LUNG CANCER

Daniel Morgensztern, MD, discusses both the single-agent and combination immunotherapy data in NSCLC and what researchers are poised to do next in the field.

Siddhartha Devarakonda, MD, highlights the importance of testing for molecular markers, some of the rarer mutations, and what work lies ahead for the field of NSCLC.

Stereotactic body radiotherapy is safe and effective in patients ≥80 years with early-stage non–small cell lung cancer, results of a multi-center retrospective analysis showed.

Jonathan Riess, MD, discusses the game-changing efficacy of osimertinib in NSCLC and its potential in combination, considering factors for choosing an EGFR TKI, and the burgeoning questions clinicians still have with the<em> EGFR</em>-mutant population.

Brigatinib has been granted an accelerated approval by the FDA as a treatment for patients with metastatic <em>ALK</em>-positive non&ndash;small cell lung cancer who are resistant to prior crizotinib.

The molecular profile of a patient with cancer who is about to be treated for their metastatic disease is the most critical piece of information you can have for that patient, according to Howard A. &ldquo;Skip&rdquo; Burris III, MD.

Lorlatinib has been granted a breakthrough therapy designation by the FDA for use in patients with <em>ALK</em>-positive metastatic non-small cell lung cancer who have previously received 1 or more ALK inhibitors.

Osimertinib has been granted a full approval by the European Union for the treatment of patients with locally advanced or metastatic <em>EGFR T790M&nbsp;</em>mutation-positive non&ndash;small cell lung cancer, regardless of prior treatment with an EGFR TKI.

Matthew Gubens, MD, sheds light on how far the field has come with molecular testing, the challenges still ahead, and what novel assays could be on the horizon.

Immunotherapy has made a significant impact in the field of non&ndash;small cell lung cancer. However, as more research unravels, investigators are unsure which set of combinations will have the most positive effect on their patients with advanced disease.

Veliparib fell short of meeting the primary endpoint&nbsp;in a phase III non&ndash;small cell lung cancer trial and a triple-negative breast cancer trial.

Geoffrey R. Oxnard, MD, discusses a study that found overgrowth of competing resistance mechanisms, such as an acquired <em>KRAS</em> mutation, underlies a poor prognosis subtype of acquire resistance to osimertinib in T-790M-positive non-small cell lung cancer.

Advanced Squamous Non-Small Cell Lung Cancer

Advanced Squamous Non-Small Cell Lung Cancer

Nuances in Treating Squamous Cell Lung Cancer

Leena Gandhi, MD, PhD, discusses&nbsp;the ongoing phase III ALEX study, which is exploring alectinib as a first-line treatment option for&nbsp;<em>ALK</em>-positive non&ndash;small cell lung cancer.

Julie R. Brahmer, MD, discusses&nbsp;5-year follow-up data from the CA209-003 study of nivolumab for patients with metastatic non&ndash;small cell lung cancer.

Sukhmani Padda, MD, discusses&nbsp;the status of ongoing trials participating in the race to the frontline in lung cancer.

According to findings from the phase III ALEX trial, alectinib reduced the risk of disease progression or death compared with crizotinib as a frontline treatment for patients with <em>ALK</em>-positive non&ndash;small cell lung cancer.&nbsp;